

## New from NICE

---

**Technology Appraisal. Rituximab in combination with glucocorticoids for treating antineutrophil cytoplasmic antibody-associated vasculitis. TA308**

**Recommended**

NICE has recommended rituximab (MabThera), in combination with glucocorticoids, as an option for inducing

remission in adults with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. It is limited to patients for whom cyclophosphamide treatment is not appropriate or has failed after a course lasting three to six months, or who have had uroepithelial malignancy (a complication of cyclophosphamide therapy).

Rituximab is a monoclonal antibody that depletes CD20 B cells. Clinicians told NICE it was 'scene changing' in this indication. NICE agreed it was innovative, justifying a higher cost per QALY. Estimates of its cost effectiveness were uncertain but a figure below £30 000 per QALY was likely for individuals unable to have treatment with cyclophosphamide.